Zhi Tong Cai Jing·2025-11-11 06:37Core Viewpoint - Haitong International has raised its revenue forecasts for BeiGene (06160) due to the stronger-than-expected market uptake of Zebrutinib in the US and European markets [1] Revenue Forecast - The revenue projections for BeiGene for the years 2025, 2026, and 2027 have been adjusted to $5.3 billion, $6.4 billion, and $7.1 billion respectively, reflecting a compound annual growth rate (CAGR) of 23% [1] Net Profit Adjustment - The net profit estimates for BeiGene have been revised to $360 million, $660 million, and $1.05 billion for the same years, indicating that the growth in sales and R&D expenses is better than anticipated [1] Target Price and Rating - Based on a weighted average cost of capital of 9% and a perpetual growth rate of 4%, the target price for BeiGene is set at HKD 213.1, maintaining an "Outperform" rating [1]